Lynparza receives positive EU CHMP opinion for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer
AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate an improvement in progression-free survival for patients in this settingAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending Lynparza (olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer. The recommendation is for the use of Lynparza tablets as a maintenance treatment of adult